Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | PTGS2 | P35354 | 12/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.62 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.62 |
| ▸ | HTR1A | P08908 | 1/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.62 |
| ▸ | MC4R | P32245 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29612591 | 1.00 | KMT2A (0.67) | KMT2APTGS2PTGS1ABCB11ALDH1A1 | |
| SCHEMBL2127606 | 1.00 | KMT2A (0.67) | KMT2APTGS2PTGS1ABCB11ALDH1A1 | |
| SCHEMBL2132370 | 1.00 | KMT2A (0.67) | KMT2APTGS2PTGS1ABCB11ALDH1A1 | |
| SCHEMBL29612583 | 1.00 | KMT2A (0.67) | KMT2APTGS2PTGS1ABCB11ALDH1A1 | |
| SCHEMBL22158009 | 0.91 | KMT2A (0.55) | KMT2APTGS2PTGS1ABCB11ALDH1A1 | |
| SCHEMBL17378083 | 0.88 | PTGS2 (0.64) | KMT2APTGS2PTGS1ABCB11ALDH1A1 | |
| SCHEMBL7053045 | 0.82 | PTGS2 (0.44) | KMT2APTGS2PTGS1ABCB11ALDH1A1 | |
| SCHEMBL5071823 | 0.82 | KMT2A (1.00) | KMT2APTGS2PTGS1ABCB11ALDH1A1 | |
| SCHEMBL13743029 | 0.79 | KMT2A (0.79) | KMT2APTGS2PTGS1ABCB11ALDH1A1 | |
| SCHEMBL26996609 | 0.78 | KMT2A (0.76) | KMT2APTGS2PTGS1ABCB11ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11872206-B2 | Purified forms of rofecoxib, methods of manufacture and use | Tremeau Pharmaceuticals, Inc. (US) | 2024-01-16 | — | — | US | claimed |
| US-11617735-B2 | Purified forms of rofecoxib, methods of manufacture and use | Tremeau Pharmaceuticals, Inc. (US) | 2023-04-04 | — | — | US | claimed |
| US-11576890-B2 | Purified forms of rofecoxib, methods of manufacture and use | Tremeau Pharmaceuticals, Inc. (US) | 2023-02-14 | — | — | US | claimed |
| US-11559509-B2 | Purified forms of rofecoxib, methods of manufacture and use | Tremeau Pharmaceuticals, Inc. (US) | 2023-01-24 | — | — | US | claimed |
| US-20220409568-A1 | PURIFIED FORMS OF ROFECOXIB, METHODS OF MANUFACTURE AND USE | Tremeau Pharmaceuticals, Inc. (US) | 2022-12-29 | — | — | US | claimed |
| US-20220378736-A1 | PURIFIED FORMS OF ROFECOXIB, METHODS OF MANUFACTURE AND USE | Tremeau Pharmaceuticals, Inc. (US) | 2022-12-01 | — | — | US | claimed |
| US-20220362206-A1 | PURIFIED FORMS OF ROFECOXIB, METHODS OF MANUFACTURE AND USE | Tremeau Pharmaceuticals, Inc. (US) | 2022-11-17 | — | — | US | claimed |
| CN-113660934-A | Purified forms, methods of preparation and uses of rofecoxib | 特默罗制药股份有限公司 | 2021-11-16 | — | — | CN | claimed |
| US-20210236455-A1 | PURIFIED FORMS OF ROFECOXIB, METHODS OF MANUFACTURE AND USE | Tremeau Pharmaceuticals, Inc. (US) | 2021-08-05 | — | — | US | claimed |
| US-10987337-B2 | Purified forms of rofecoxib, methods of manufacture and use | Tremeau Pharmaceuticals, Inc. (US) | 2021-04-27 | — | — | US | claimed |
| US-20200206182-A1 | PURIFIED FORMS OF ROFECOXIB, METHODS OF MANUFACTURE AND USE | Tremeau Pharmaceuticals, Inc. | 2020-07-02 | — | — | US | claimed |
| WO-2012052180-A1 | COMBINATIONS COMPRISING DHODH INHIBITORS AND COX INHIBITORS | ALMIRALL, S.A. (ES) | 2012-04-26 | — | — | WO | claimed |
| EP-2444086-A1 | Combinations comprising DHODH inhibitors and COX inhibitors | Almirall, S.A. (ES) | 2012-04-25 | — | — | EP | claimed |
| US-20060189684-A1 | 3-Phenylfuran-2-one derivatives as cox-2 inhibitor | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-08-24 | — | — | US | claimed |
| JP-2006517561-A | — | — | 2006-07-27 | — | — | JP | claimed |
| EP-1592678-A1 | 3-PHENYLFURAN-2-ONE DERIVATIVES AS COX-2 INHIBITOR | Almirall Prodesfarma, S.A. (ES) | 2005-11-09 | — | — | EP | claimed |
| WO-2004072057-A1 | 3-PHENYLFURAN-2-ONE DERIVATIVES AS COX-2 INHIBITOR | ALMIRALL PRODESFARMA S.A. (ES) | 2004-08-26 | — | — | WO | claimed |
| US-11872206-B2 | Purified forms of rofecoxib, methods of manufacture and use | Tremeau Pharmaceuticals, Inc. (US) | 2024-01-16 | — | — | US | disclosed |
| WO-2004093811-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A SODIUM ION CHANNEL BLOCKER FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004072057-A1 | 3-PHENYLFURAN-2-ONE DERIVATIVES AS COX-2 INHIBITOR | ALMIRALL PRODESFARMA S.A. (ES) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10987337-B2 | Purified forms of rofecoxib, methods of manufacture and use | ITGA2B, F13B, F11 | KMT2A 1173/4885PTGS2 764/4885PTGS1 581/4885 |
| US-20220378736-A1 | PURIFIED FORMS OF ROFECOXIB, METHODS OF MANUFACTURE AND USE | ITGA2B, F13B, F11 | KMT2A 1173/4885PTGS2 764/4885PTGS1 581/4885 |
| US-20210236455-A1 | PURIFIED FORMS OF ROFECOXIB, METHODS OF MANUFACTURE AND USE | ITGA2B, F13B, F11 | KMT2A 1173/4885PTGS2 764/4885PTGS1 581/4885 |
| US-11872206-B2 | Purified forms of rofecoxib, methods of manufacture and use | ITGA2B, F13B, F11 | KMT2A 1173/4885PTGS2 764/4885PTGS1 581/4885 |
| US-20200206182-A1 | PURIFIED FORMS OF ROFECOXIB, METHODS OF MANUFACTURE AND USE | ITGA2B, F13B, F11 | KMT2A 1173/4885PTGS2 764/4885PTGS1 581/4885 |
| US-11617735-B2 | Purified forms of rofecoxib, methods of manufacture and use | ITGA2B, F13B, F11 | KMT2A 1173/4885PTGS2 764/4885PTGS1 581/4885 |
| US-20220362206-A1 | PURIFIED FORMS OF ROFECOXIB, METHODS OF MANUFACTURE AND USE | ITGA2B, F13B, F11 | KMT2A 1173/4885PTGS2 764/4885PTGS1 581/4885 |
| US-20060189684-A1 | 3-Phenylfuran-2-one derivatives as cox-2 inhibitor | PTGS2, PTGES2, PTGS1 | KMT2A 2864/4885PTGS2 1/4885PTGS1 3/4885 |
| US-11559509-B2 | Purified forms of rofecoxib, methods of manufacture and use | ITGA2B, F13B, F11 | KMT2A 1173/4885PTGS2 764/4885PTGS1 581/4885 |
| US-11576890-B2 | Purified forms of rofecoxib, methods of manufacture and use | ITGA2B, F13B, F11 | KMT2A 1173/4885PTGS2 764/4885PTGS1 581/4885 |
| US-20220409568-A1 | PURIFIED FORMS OF ROFECOXIB, METHODS OF MANUFACTURE AND USE | ITGA2B, F13B, F11 | KMT2A 1173/4885PTGS2 764/4885PTGS1 581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.